Kymera Investor Presentation Deck

● ● ● Adverse Events Related to KT-474 (Occurring in >1 Patient) Adverse Event (Preferred Term) KYMERA Headache Fatigue Diarrhea # of Patients 6 Ⓒ2023 KYMERA THERAPEUTICS, INC. 4 2 Severity (# of Pts) Mild (5) Severe (1) Mild (4) Mild (2) Outcome (# of Pts) Recovered (6) Recovered (4) No SAEs, no drug-related infections, and no AEs observed leading to dose interruption or discontinuation No QTc-related AEs observed Recovered (2) QTc declines to baseline with continued dosing and sustained plasma exposure through Day 28 Profile is maintained through day 42 upon cessation of dosing after Day 28 IRAK4 Patients PAGE 18

View entire presentation